FGF2 and lung carcinoma: Anti-S1P antibodies reduced the expression and activity of hypoxia-inducible factor 1α (HIF-1α), secretion of the angiogenic factors IL-6, IL-8, vascular endothelial growth factor (VEGF), and basic fibroblastic growth factor (bFGF) and decreased vessel formation in in vitro and in vivo models of ovarian, breast, prostate and lung cancers[95–97].